Venture. CorNova shall focus its resources on the development and marketing of innovative interventional cardiology products. The initial target of CorNova is the development of a next-generation drug-eluting stent. CorNova will direct its resources to develop or acquire technology relating to stent design, CE testing and drug coatings, including but not limited to Chronoflex DES polymer or any polycarbonatepolyurethane and containing derivative thereof for use on drug-eluting stents. Utilizing the combined capabilities of the Participants, CorNova will seek to produce a novel coronary stent system whose design, materials, and manufacturing will be specific for drug elution technology.
Appears in 2 contracts
Sources: Exchange & Venture Agreement (Implant Sciences Corp), Exchange & Venture Agreement (Cardiotech International Inc)
Venture. CorNova shall focus its resources on the development and marketing of innovative interventional cardiology products. The initial target of CorNova is the development of a next-generation drug-eluting stent. CorNova will direct its resources to develop or acquire technology relating to stent design, CE testing and drug coatings, including but not limited to Chronoflex DES polymer or any polycarbonatepolyurethane polycarbonatepolyurethane and containing derivative thereof for use on drug-eluting stents. Utilizing the combined capabilities of the Participants, CorNova will seek to produce a novel coronary stent system whose design, materials, and manufacturing will be specific for drug elution technology.
Appears in 1 contract
Sources: Exchange & Venture Agreement (Cardiotech International Inc)